Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Illegal ED product ingredients

This article was originally published in The Tan Sheet

Executive Summary

Erectile dysfunction and sexual enhancement drug products distributed by Shangai Distributor of Puerto Rico are labeled as dietary supplements but are actually unapproved, FDA reports Dec. 28. The products, which originated in China, contain undeclared active ingredients used in FDA-approved prescription ED drugs. Sildenafil, the active ingredientinViagra, was found in the firm's Super Shangai, Strong Testis, Shangai Ultra X and Lady Shangai, while Shangai Regular was found to contain a similar unapproved substance...

You may also be interested in...

“Promising” Trend: FDA Acts On Unapproved Drugs, Tainted Supplements

U.S. Marshals' seizure of unapproved erectile dysfunction drugs from Shangai Distributors may be evidence of a promising trend of FDA following through on warning letters to companies marketing unapproved new drugs mislabeled as supplements, according to food and drug attorney Marc Ullman

'Covidization' Of Resources Brings Huge Disruption For TB Patients, Researchers

Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.

Perrigo’s Albuterol Advantage Blunted By Recall

After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts